ReviewAging medicine (Milton (N.S.W))2021
Advances in research on pharmacotherapy of sarcopenia.
Review in Aging medicine (Milton (N.S.W)), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The potential of acupuncture in treating sarcopenia: a systematic review and meta-analysis of randomized controlled trials.Frontiers in public health · 2025Pooled it
- Regenerative Medicine: Advanced Therapy for Muscle Tissue Restoration.International journal of molecular sciences · 2026Review
- Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Transcriptomic characterization of the aberrant alternative splicing in skeletal muscles of sarcopenia patients.Scientific reports · 2026Article
- Umbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.Stem cell research & therapy · 2025Review
- Mechanical Stimulation Induces Yap Mediated OCTN2 Transcription to Enhance Carnitine Metabolism in Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2025Article
- Latest Updates on Sarcopenia and Cachexia: Insights from the 17th Sarcopenia, Cachexia, and Wasting Disorders Conference.Journal of bone metabolism · 2025Article
- Advancing muscle aging and sarcopenia research through spatial transcriptomics.Osteoporosis and sarcopenia · 2025Review
- Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone.Journal of cachexia, sarcopenia and muscle · 2025Article
- Osteosarcopenia in metabolic dysfunction-associated steatotic liver disease: from mechanisms to management.Frontiers in endocrinology · 2025Review
- Exploration of Pathogenesis and Cutting-Edge Treatment Strategies of Sarcopenia: A Narrative Review.Clinical interventions in aging · 2025Review
- Regulation of SLC7A11 by LncRNA GPRC5D-AS1 mediates ferroptosis in skeletal muscle: Mechanistic exploration of sarcopenia.Frontiers in molecular biosciences · 2025Article
- Advancements in Drug Delivery Systems for the Treatment of Sarcopenia: An Updated Overview.International journal of molecular sciences · 2024Review
- Resistance Training and Nutritional Supplementation in Older Adults with Sarcopenia after Acute Disease: A Feasibility Study.Nutrients · 2024Article
- Cyclo His-Pro Attenuates Muscle Degeneration in Murine Myopathy Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Emerging Therapeutic Strategies in Sarcopenia: An Updated Review on Pathogenesis and Treatment Advances.International journal of molecular sciences · 2024Review
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease.World journal of gastroenterology · 2024Article
- Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management.Journal of the ASEAN Federation of Endocrine Societies · 2024Review
- Subcutaneous Infusion of DNA-Aptamer Raised against Advanced Glycation End Products Prevents Loss of Skeletal Muscle Mass and Strength in Accelerated-Aging Mice.Biomedicines · 2023Article
- Causal relationship between sarcopenia and osteoarthritis: a bi-directional two-sample mendelian randomized study.European journal of medical research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a comprehensive degenerative disease with the progressive loss of skeletal muscle mass with age, accompanied by the loss of muscle strength and muscle dysfunction. As a new type of senile syndrome, sarcopenia seriously threatens the health of the elderly. The first-line treatment for sarcopenia is exercise and nutritional supplements. However, pharmacotherapy will provide more reliable and sustainable interventions in geriatric medicine. Clinical trials of new drugs targeting multiple molecules are ongoing. This article focuses on the latest progress in pharmacotherapeutic approaches of sarcopenia in recent years by comprehensively reviewing the clinical outcomes of the existing and emerging pharmacotherapies as well as the molecular mechanisms underlying their therapeutic benefits and side effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.